Invention Publication
- Patent Title: NLRP3 INFLAMMASOME SMALL-MOLECULE INHIBITOR FOR TREATMENT OF ALZHEIMER'S DISEASE
-
Application No.: US18275470Application Date: 2022-01-28
-
Publication No.: US20240132458A1Publication Date: 2024-04-25
- Inventor: Sangdun CHOI , Muhammad HASEEB , Javaid NASIR , Yasmeen FARZANA , Jee Yeon SEO , Jae Kyung HEO , Ho Chul SHIN
- Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Applicant Address: KR Suwon-si, Gyeonggi-do
- Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee Address: KR Suwon-si, Gyeonggi-do
- Priority: KR 20210015425 2021.02.03
- International Application: PCT/KR2022/001620 2022.01.28
- Date entered country: 2023-08-02
- Main IPC: C07D277/82
- IPC: C07D277/82 ; A61P25/28 ; C07D417/12

Abstract:
A NLRP3-inhibitory compound 7 (NIC7) and a potent derivative NIC7w are disclosed. NLRP3-inhibitory compound 7 (NIC7) and a potent derivative NIC7w are a novel small-molecule inhibitor for inhibiting NLRP3 inflammasomes are identified. These compounds inhibit main elements of the NLRP3 signaling pathway, primarily IL-1β and caspase 1, and improve cognitive behaviors of mice in Alzheimer disease mouse models. Compositions of NIC7 and NIC7w are suitable as a therapeutic agent in treating, preventing, or improving the conditions of Alzheimer's disease.
Information query